Roche Holding (ROCH) Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details

ROCH fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 58.3% below our estimate of its fair value

Earnings are forecast to grow 13.9% per year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Profit margins (13.3%) are lower than last year (19%)

Dividend of 3.71% is not well covered by earnings

ROCH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Roche Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Roche Holding
Historical stock prices
Current Share Price	CHF 279.50
52 Week High	CHF 289.80
52 Week Low	CHF 265.40
Beta	0.17
1 Month Change	-1.65%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.93%

Recent updates

Shareholder Returns

	ROCH	AT Pharmaceuticals	AT Market
7D	0.6%	-1.2%	1.4%
1Y	n/a	-21.6%	16.4%

Return vs Industry: Insufficient data to determine how ROCH performed against the Austrian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ROCH performed against the Austrian Market.

Price Volatility

Is ROCH's price volatile compared to industry and market?
ROCH volatility
ROCH Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	4.7%
10% most volatile stocks in AT Market	6.9%
10% least volatile stocks in AT Market	3.0%

Stable Share Price: ROCH has not had significant price volatility in the past 3 months compared to the Austrian market.

Volatility Over Time: Insufficient data to determine ROCH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROCH fundamental statistics
Market cap	€224.10b
Earnings (TTM)	€8.84b
Revenue (TTM)	€66.65b

25.1x

P/E Ratio

3.3x

P/S Ratio

Is ROCH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROCH income statement (TTM)
Revenue	CHF 62.40b
Cost of Revenue	CHF 15.73b
Gross Profit	CHF 46.66b
Other Expenses	CHF 38.39b
Earnings	CHF 8.28b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 24, 2025

Earnings per share (EPS)	10.41
Gross Margin	74.79%
Net Profit Margin	13.27%
Debt/Equity Ratio	95.9%

How did ROCH perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

93%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/30 20:13
End of Day Share Price	2025/06/27 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 59 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research